Literature DB >> 21987675

Modified 23-gauge vitrectomy system for stage 4 retinopathy of prematurity.

Wei-Chi Wu1, Chi-Chun Lai, Rey-In Lin, Nan-Kai Wang, An-Ning Chao, Kuan-Jen Chen, Tun-Lu Chen, Yih-Shiou Hwang.   

Abstract

OBJECTIVE: To evaluate the outcome of a novel, modified 23-gauge vitrectomy system in the treatment of stage 4 retinal detachment in retinopathy of prematurity.
METHODS: Consecutive patients with stage 4 retinopathy of prematurity treated with modified 23-gauge vitrectomy were included in this medical record review. Major novel modifications included the use of a small infusion cannula, a 20-gauge blade for the creation of sclerotomies in the pars plicata, and a 23-gauge endoilluminator and vitreous cutter. Conjunctival dissection and suturing of sclerotomies were performed using this modified 3-port, 23-gauge vitrectomy technique. Anatomic success and surgical complications were analyzed.
RESULTS: Twenty-six eyes of 17 patients were included and analyzed. The mean (SD) gestational age was 28.0 (2.5) weeks, and the mean birth weight was 1199 (449) g. Mean postmenstrual age at the time of vitrectomy was 40.5 (3.0) weeks. Overall, 20 eyes (77%) achieved retinal attachment in a single operation, and 23 eyes (88%) achieved retinal attachment after multiple procedures. Postoperative complications included disc dragging (5 eyes [19%]), cataracts (4 [15%]), glaucoma (2 [8%]), persistent vitreous hemorrhage (1 [4%]), and posterior synechia (1 [4%]).
CONCLUSIONS: This 23-gauge vitrectomy system seems to be a safe and effective approach for treatment of stage 4 retinopathy of prematurity. This modified system combines the benefits of 20- and 23-gauge vitrectomy and offers safer insertion of infusion cannulas in smaller eyes, more working space in pediatric eyes, a cutting port that is closer to the retina, and a faster cutting speed with less vitreous traction during the operation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21987675     DOI: 10.1001/archophthalmol.2011.253

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  7 in total

Review 1.  New insights in diagnosis and treatment for Retinopathy of Prematurity.

Authors:  Linda A Cernichiaro-Espinosa; Francisco J Olguin-Manriquez; Andree Henaine-Berra; Gerardo Garcia-Aguirre; Hugo Quiroz-Mercado; Maria A Martinez-Castellanos
Journal:  Int Ophthalmol       Date:  2016-01-14       Impact factor: 2.031

2.  Vitreous Bands Identified by Handheld Spectral-Domain Optical Coherence Tomography Among Premature Infants.

Authors:  Emily M Zepeda; Ayesha Shariff; Thomas B Gillette; Laura Grant; Leona Ding; Kristina Tarczy-Hornoch; Michelle T Cabrera
Journal:  JAMA Ophthalmol       Date:  2018-07-01       Impact factor: 7.389

Review 3.  Retinopathy of prematurity treatment: Asian perspectives.

Authors:  Parveen Sen; Wei-Chi Wu; Parijat Chandra; Anand Vinekar; Pradeep T Manchegowda; Pramod Bhende
Journal:  Eye (Lond)       Date:  2019-10-29       Impact factor: 3.775

4.  Characteristics of Eyes Developing Retinal Detachment After Anti-vascular Endothelial Growth Factor Therapy for Retinopathy of Prematurity.

Authors:  Chiori Kondo; Chiharu Iwahashi; Shoko Utamura; Kazuki Kuniyoshi; Yuhei Konishi; Norihisa Wada; Ryo Kawasaki; Shunji Kusaka
Journal:  Front Pediatr       Date:  2022-04-07       Impact factor: 3.418

5.  Hybrid clear corneal micro-incision surgical technique for stage 5 retinopathy of prematurity.

Authors:  Parijat Chandra; Devesh Kumawat; Ruchir Tewari
Journal:  Indian J Ophthalmol       Date:  2019-06       Impact factor: 1.848

6.  Evaluation of segmental scleral buckling surgery for stage 4A retinopathy of prematurity in China.

Authors:  Yusheng Zhong; Yating Yang; Hong Yin; Mingwei Zhao; Xiaoxin Li; Jianhong Liang; Yong Cheng
Journal:  Front Med (Lausanne)       Date:  2022-08-03

7.  Long-term clinical prognosis of 335 infant single-gene positive FEVR cases.

Authors:  Chunli Chen; Yizhe Cheng; Zhihan Zhang; Xiang Zhang; Jiakai Li; Peiquan Zhao; Xiaoyan Peng
Journal:  BMC Ophthalmol       Date:  2022-08-02       Impact factor: 2.086

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.